Amber Bio

Amber Bio is a biotechnology company based in the United States. This small company, with 2 employees, has generated $2.5 million in revenue. Amber Bio is pioneering new gene editing modalities using multi-kilobase edits to target previously unreachable patient populations. Their focus is on developing a revolutionary RNA writing platform capable of addressing thousands of diverse mutations across patients with a single product, shifting away from the current model of independent therapies for each unique mutation. The company's innovative approach is driven by a team of founders who are pioneers in the CRISPR field and hold expertise from renowned gene editing research institutions. For more information, visit Amber Bio's website at amber.bio.